ENTITY
Shanghai HeartCare Medical Technology

Shanghai HeartCare Medical Technology (6609 HK)

32
Analysis
Health CareChina
Shanghai HeartCare Medical Technology Corporation Limited develops and manufactures neuro-interventional medical devices. The Company produces ischemic stroke prevention devices, ischemic stroke thrombectomy devices, intracranial stenosis treatment devicies, vacular access devices, and more. Shanghai HeartCare Medical Technology conducts business in China.
more
Refresh
22 Aug 2021 10:21

ECM Weekly (22nd August 2021) - Biel Crystal, EDDA, Neusoft Xikang and Medical, CATL, RLC REIT

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
19 Aug 2021 19:29

Shanghai Heartcare IPO: Thoughts on First Day Trading

We expect Heartcare’s IPO to remain under pressure at its open due to uncertainty regarding the lawsuit with Medtronics despite being priced at a...

Share
19 Aug 2021 10:58

Heartcare (心玮医疗) IPO Trading: Risk-Off for Institutional Investors

We analyze the new information for HeartCare IPO. We think the demand is not strong and debut performance will be under pressure given the overhang...

Logo
235 Views
Share
15 Aug 2021 14:20

Acotec Scientific IPO: Valuation Insights

Our base-case DCF valuation is HK$21.65 per share, which is a -6% downside to the mid-point of the IPO price range. Consequently, we think the...

Logo
298 Views
Share
12 Aug 2021 13:56

Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic

Our DCF valuation offers a price per share of HK$182.78 which is 6.9% higher than the upper end of the company’s indicative IPO price range of...

Share
x